Preliminary results with the antiprogestational compound RU-486 (mifepristone) for interruption of early pregnancy.
RU-486 (mifepristone) (Roussel-Uclaf, Paris, France) is an antiprogesterone that acts through a competitive binding at the site of the progesterone and cortisol receptor. It induced a complete expulsion in 29 (83%) of 35 patients with an unwanted pregnancy with up to 55 days of amenorrhea. A complete expulsion occurred in 17 (89%) of the 19 nulliparous women, and no serious side effects were seen. However, our results were less successful in ine patients with a more advanced pregnancy (between 8 and 10 weeks). In this group, only three complete expulsions were seen.
Vervest
H A
HA
Haspels
A A
AA
D000028:Abortion, Induced; D001667:Binding, Competitive; D006063:Chorionic Gonadotropin / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human; D015232:Dinoprostone / Q000031:analogs & derivatives*; D004958:Estradiol / Q000097:blood; D004963:Estrenes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D015735:Mifepristone; D010446:Peptide Fragments / Q000097:blood; D011374:Progesterone / Q000097:blood; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use; D011965:Receptors, Glucocorticoid / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D004963:Estrenes; D010446:Peptide Fragments; D011459:Prostaglandins E, Synthetic; D011965:Receptors, Glucocorticoid; D011980:Receptors, Progesterone; C029360:hydrocortisone receptor; D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol; C016767:sulprostone; D015232:Dinoprostone; D006854:Hydrocortisone